Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies

Reply from Authors re: Bertrand Tombal. Zometa European Study (ZEUS): Another Failed Crusade for the Holy Grail of Prostate Cancer Bone Metastases Prevention? Eur Urol 2015;67:492–4

(2015) Wim P.J. Witjes et al.   EUROPEAN UROLOGY

Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer

(2015) Karim Fizazi et al.   EUROPEAN UROLOGY

Zometa European Study (ZEUS): Another Failed Crusade for the Holy Grail of Prostate Cancer Bone Metastases Prevention?

(2015) Bertrand Tombal   EUROPEAN UROLOGY

Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)

(2015) Manfred Wirth et al.   EUROPEAN UROLOGY

Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the end point's definition?

(2014) B. Tombal   ANNALS OF ONCOLOGY

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

(2014) M. R. Smith et al.   ANNALS OF ONCOLOGY

Dickkopf-1 as a mediator and novel target in malignant bone disease

(2014) Tilman D. Rachner et al.   CANCER LETTERS

Muscle and bone effects of androgen deprivation therapy: current and emerging therapies

(2014) A. S. Cheung et al.   ENDOCRINE-RELATED CANCER

Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone

(2014) P. D. Ottewell et al.   ENDOCRINE-RELATED CANCER

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

(2014) Matthew R. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

(2014) Matthew R. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial

(2014) Karim Fizazi et al.   LANCET ONCOLOGY

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

(2014) Oliver Sartor et al.   LANCET ONCOLOGY

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

(2014) Michael R. McClung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endocrine aspects of bone metastases

(2014) Lorenz C Hofbauer et al.   Lancet Diabetes & Endocrinology

Androgens and prostate cancer; pathogenesis and deprivation therapy

(2013) Mathis Grossmann et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced pr

(2013) James W. Denham et al.   BJU INTERNATIONAL

Failure to Suppress Markers of Bone Turnover on First-Line Hormone Therapy for Metastatic Prostate Cancer Is Associated With Shorter Time to Skeletal-Related Event

(2013) Noah M. Hahn et al.   Clinical Genitourinary Cancer

EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer

(2013) Axel Heidenreich et al.   EUROPEAN UROLOGY

Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer

(2013) Karim Fizazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time

(2013) Matthew R. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids

(2013) B. García-Fontana et al.   OSTEOPOROSIS INTERNATIONAL

Cancer-associated bone disease

(2013) R. Rizzoli et al.   OSTEOPOROSIS INTERNATIONAL

Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid

(2013) Roger von Moos et al.   SUPPORTIVE CARE IN CANCER

Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems

(2013) Gerry Oster et al.   SUPPORTIVE CARE IN CANCER

Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A

(2012) Yalcin Cirak et al.   BJU INTERNATIONAL

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

(2012) Joel B. Nelson et al.   CANCER

Male Osteoporosis

(2012) Matthew T. Drake et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial

(2012) Karim Fizazi et al.   JOURNAL OF UROLOGY

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial

(2012) Christopher J Logothetis et al.   LANCET ONCOLOGY

Muscles, exercise and obesity: skeletal muscle as a secretory organ

(2012) Bente K. Pedersen et al.   Nature Reviews Endocrinology

Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?

(2012) Tilman Todenhöfer et al.   WORLD JOURNAL OF UROLOGY

Niche competition and cancer metastasis to bone

(2011) Laura G. Schuettpelz et al.   JOURNAL OF CLINICAL INVESTIGATION

Osteoporosis: now and the future

(2011) Tilman D Rachner et al.   LANCET

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

(2011) A Serpa Neto et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Bone health management in prostate cancer patients receiving androgen deprivation therapy

(2011) Vishnuprabha Dhanapal et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases

(2010) Nanda K. Thudi et al.   PROSTATE

Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation

(2009) Ronald R. Gomes et al.   CLINICAL & EXPERIMENTAL METASTASIS

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

(2009) David P Dearnaley et al.   LANCET ONCOLOGY

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE